HONG KONG, Jun 9, 2026 - (ACN Newswire) - Everest Medicines today announced that it has entered into an exclusive licensing agreement with Jiangsu Vcare PharmaTech Co., Ltd. (“Vcare”), for the development, registration and commercialization of Sumecigrel (formerly known as Vicagrel) across the Asia-Pacific region, including Southeast Asia, South Korea, Australia, Hong Kong SAR, Macao SAR, and Taiwan region, China. Pursuant to the agreement, Everest Medicines will pay Vcare PharmaTech an upfront payment of RMB 20 million, along with subsequent milestone payments and commercial supply procurement.This collaboration strengthens the Company’s cardiovascular portfolio and highlights Everest’s continued focus on the Asia-Pacific market, supporting the advancement of its regional strategy and the development of innovative therapies.
Sumecigrel is an antiplatelet agent and a new-generation oral P2Y12 receptor antagonist. It is being clinically developed for the treatment and prevention of atherothrombotic events such as acute coronary syndrome (ACS), ischemic s****e (IS) and peripheral arterial disease (PAD). As a novel antithrombotic Medication self-developed by Vcare PharmaTech, the product is currently advancing preparations for NDA in China, the United States, Europe.
The molecular design of Sumecigrel targets the black box warning associated with clopidogrel resistance. It innovatively optimizes the metabolic pathway of clopidogrel while retaining its active metabolite, striking a better balance between therapeutic benefits and bleeding risks inherent to antiplatelet medications. Featuring faster onset of action, lower dosage, more stable efficacy, better controllable bleeding risks, reduced metabolic burden and broader clinical applicability, Sumecigrel is a novel antiplatelet candidate with prominent Best-in-Class potential. It is expected to address the increasingly personalized demands for antithrombotic therapy and become a blockbuster product in the antithrombotic market.
Cardio-cerebrovascular diseases rank among the leading causes of d**** worldwide. Related fatalities rose sharply to 17.9 million in 2019, accounting for approximately 32% of all global d**** s. Around 85% of these d**** s were attributed to myocardial infarction (a major type of ACS) and brain attack. The d**** toll from cardio-cerebrovascular diseases further climbed to 19.2 million in 2023.
Antiplatelet d***s inhibit platelet activation, adhesion and aggregation to reduce thrombotic risks, and are widely used for the prevention and treatment of atherothrombotic diseases. P2Y12 receptor antagonists are a major category of mainstream antiplatelet medications. Currently marketed products in this class continue to face challenges in balancing variability in efficacy and bleeding risk across patients, and optimizing the overall clinical benefit–risk profile remains an important unmet medical need in this therapeutic area.
“This collaboration with Vcare PharmaTech marks another step in strengthening our presence in the Asia-Pacific region,” said Mr. Yifang Wu, Chairman of the Board of Everest Medicines. “Sumecigrel is a next-generation oral P2Y12 receptor antagonist with Best-in-Class potential, offering differentiated clinical benefits and complementing Everest’s cardiovascular pipeline. Leveraging our clinical, regulatory, and commercial capabilities across the Asia-Pacific as a global platform for innovative therapies.
Click Here